Dostarlimab-gxly demonstrated high rates of sustained clinical complete response that allowed eligible patients to avoid chemotherapy, radiation, and surgery.

The application for the next-generation mitomycin formulation is supported by 3-month complete response data from the phase 3 UTOPIA trial.

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for rezafungin (Rezzayo ®) for the prophylaxis of invasive fungal disease.

Strong recommendations made for semiannual surveillance for HCC, testing and vaccination for hepatitis A and B.

The Food and Drug Administration (FDA) has expanded the approval of Ryzumvi ® (phentolamine ophthalmic solution 0.75%) to include the treatment of presbyopia in adults.

Researchers found that mean serum potassium was 4.16 and 4.18mmol/L in the group assigned DASH-patterned groceries and the self-directed group, respectively.

HealthDay News — Structured support may attenuate weight gain after cessation of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), according to a study published online October 7 in Obesity ...

HealthDay News — Undeclared pharmacologically active ingredients (UPAIs) are detected in one-third of over-the-counter (OTC) skin products marketed online, according to a study published online ...

The newly approved autoinjector provides an alternative to the prefilled syringe for daily self-administration.

The FDA has granted over-the-counter approval to Brytly (apraclonidine ophthalmic solution 0.125%) for the symptomatic relief of eye redness due to minor irritation in individuals aged 12 years and ...

Experts at the 2026 Fall Clinical Dermatology Conference review landmark drug approvals, emerging pipelines, and updated ...

Real-world data from Fall Clinical 2026 reveal widespread treatment dissatisfaction, anxiety, and steroid hesitancy among ...